Thus, HOTAIRM1 is a better predictor of glioma patient survival than age, tumor grade, IDH mutation status, chemotherapy, and radiotherapy (Supplementary Figure 3A–3F). This evidence concerns the gene HOTAIRM1 and central nervous system cancer.